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Introduction
Multiple myeloma (MM) is a malignant plasma-cell 
neoplasm that is characterised by an excess of mature B-cells 
in the bone marrow (plasmacytosis), in association with 
secretion of monoclonal immunoglobulins (Ig) in serum and/
or urine, decreased normal Ig and lytic bone disease.1,2 MM 
accounts for 10% to 20% of all malignant haematological 
cancers and myeloma patients often have extensive 
skeletal destruction, which are a main cause of morbidity 
and mortality.2-4 Although MM can be treated, the disease 
ultimately relapses in most cases and becomes increasingly 
resistant to therapy until conventional options are exhausted, 
prompting an urgent need for novel treatment.5 Major 
advances have been made in the understanding of plasma 
cell biology and the importance of the microenvironment 
in MM development6-9 in the past decade, leading to the 
development of newer agents such as thalidomide, its analog 
lenalidomide10 and the proteasome inhibitor bortezomib.11 
These agents have been used in combination with existing 
agents against MM, but prospects of a cure of MM with 
these agents is still uncertain and major limitations exist, 
such as patient resistance and toxicities relating to the use 
of these drugs.
Investigators are currently looking to immunotherapy 
as a means of treatment for MM.12,13 Tumour-directed 
monoclonal antibodies (mAb) or humoral therapy, have 
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Introduction: Multiple myeloma (MM), a malignancy of plasma cells, accounts for 10% of all 
haematological malignancies and is currently incurable. Although it can be treated, the disease 
tends to relapse after several years and becomes increasingly resistant to conventional therapy. 
Investigations into using humoral therapy for MM are now underway with a view that novel 
therapeutic agents may provide a more targeted therapy for MM. Materials and Methods: 
Here, phage display, a faster and more effi cient method compared to classical hybridoma fusion 
technology, was used as a proof-of-concept to isolate several single-chain Fragment variables 
(scFv) against Ku86. Results: Anti-Ku86 polyclonal scFvs biopanning was successful where 
third round scFvs (A450~1.1) showed a 1/3 increase in binding as compared to the fi rst round 
scFvs (A450~0.4) with 100ug/mL of antigen (purifi ed human Ku86). Subsequent selection and 
verifi cation of monoclonal antibodies using third round biopanning revealed 4 good affi nity 
binding clones ranging from A450~0.1 to A450~0.15 on 12.5ug/mL of antigen as compared to low 
binders (A450~0.07) and these antibodies bind to Ku86 in a specifi c and dose-dependent manner. 
Comparative studies were also performed with commercially available murine antibodies and 
results suggest that 2 of the clones may bind close to the following epitopes aa506-541 and aa1-
374. Conclusions: These studies using phage display provide an alternative and viable method 
to screen for antibodies quickly and results show that good affi nity antibodies against Ku86 
have been successfully isolated and they can be used for further studies on MM and form the 
basis for further development as anti-cancer therapeutic agents.
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caused much excitement since the 1970s and with the 
development of mAbs such as Rituximab (anti-CD20) and 
Campath-1H (anti-CD52) for the treatment of lymphoma 
and leukaemia.14 However, in the context of MM, the 
major milestone to be crossed in this area is the selection 
of a suitable surface antigen (Ag) to allow targeting by 
antibodies against MM cells.
The Ku heterodimer is made up of 2 sub-units of 
approximately 86 and 70kDa in higher eukaryotes which 
binds to DNA. Identifi ed in 1981 from Japanese patients 
with scleroderma-polymyositis overlap syndrome, Ku 
has now been found to play major roles in many cellular 
processes.15 Foremost, Ku86 in association with Ku70 and 
DNA protein kinase C plays a critical role in DNA repair 
especially in non-homologous end joining (NHEJ) where 
the lack of functional Ku proteins in the cell typically results 
in genomic instability and hypersensitivity to DNA damage 
as well as an increased likelihood of tumour development 
and immunodefi ciency.16-18 A comprehensive review of Ku 
and its potential role in cancer, especially myeloma, has 
been written by Gullo et al.19 Other cellular processes which 
Ku has been found to partake in include antigen-receptor-
gene arrangements (Variable [Diversity] Joining {V(D)J} 
recombination), gene transcription, apoptosis, telomere 
maintenance, heat shock-induced responses and cell cycle 
regulation20 which are important processes affecting tumour 
metastasis. Therefore, it is clear that the Ku protein has an 
integral and intrinsic role in cellular and organismal tumour 
biology. Further, Ku86 has been discovered to translocate 
to the cell surface of MM cells upon CD40L treatment21 
and also mediate the binding of MM cells to fi bronectin 
and bone marrow stromal cells.22 Most importantly, the 
mAb 5E2 directed against Ku86 were seen to induced 
apoptosis of MM cells.22 Therefore, with Ku’s role in 
tumour biology and its subsequent surface translocation, 
surface bound Ku in MM provides an attractive target for 
therapeutic antibodies.
In this present study, we have raised several monoclonal 
single-chain Fragment variable (scFv) against Ku86. 
Isolation of scFv was performed using phage display of a 
human monoclonal antibody library instead of conventional 
hybridoma technology, allowing us to bypass steps of 
humanisation of the scFv to avoid issues of human anti-
mouse antibody (HAMA) reactions commonly associated 
with antibodies produced using hybridoma. Finally, the 
isolated scFvs’ specifi cities and affi nities were compared 
to other known mAbs using competitive ELISAs.
Materials and Methods
Cell and Cell Culture
COS-7 cell line, a derivation of CV-1 which was estab-
lished from the kidney of an African green monkey, RPMI 
8226 human MM (CCL-155) and CHO-K1 (CCL-61) was 
purchased from American Type Culture Collection (ATCC, 
Rockville, MD). EBV-negative SGH-MM5 human MM 
cell line (CD10+, CD19-, CD20-, CD38+, CD40+, CD45+, 
CD56+, CD138+) was developed previously in our labo-
ratory23 from a patient with MM. COS-7 and CHO were 
cultured in complete media consisting of 89% Dulbecco’s 
modifi ed Eagle medium (DMEM), 10% fetal bovine serum 
(FBS) and 1% MEM non-essential amino acids while RPMI 
8226 and SGH-MM5 were cultured in 90% RPMI 1640 
with L-glutamine media, 10% FBS, 25IU/mL penicillin, 
25ug/mL streptomycin and additional 5mM L-glutamine. 
All cell lines were maintained at 37oC with 5% CO2 in a 
humidifi ed atmosphere.
Construction and Cloning of Ku86 gene into Mammalian 
Expression Vector
Full-length 2.4kb Ku86 cDNA was obtained by RT-
PCR using QIAGEN RT-PCR kit (QIAGEN, Hilden, 
Germany) according to manufacturers’ protocol. RT-PCR 
was performed on total RNA extracted from SGH-MM5 
and RPMI cell lines using QIAGEN RNAeasy (QIAGEN) 
kit and the following oligonucleotides, Ku1 (forward: 
5’-TGTATGGACGTGGGCTTTA CCAT-3’) and Ku2 
(reverse: 5’-TCCACAGAGAATTAGATGATCCGCC-3’). 
PCR products were then separated by 1.5% agarose 
gel electrophoresis and cloned into Topo II TA vectors 
(Invitrogen, Carlsbad, USA) for amplification in 
Escherichia coli (E. coli) with 100ug/mL ampicillin 
pressure and blue/white colony selection. Sequencing 
was performed on the cloned Ku86 gene to ensure no 
mutations. Next, 2 restriction enzyme sites, HindIII 
at 5’ end and XbaI at 3’ end were engineered at the 
ends of the cloned Ku86 using high fi delity PWO 
SuperYield DNA polymerase (Roche Diagnostics, 
Penzberg, Germany) with the following oligonucleotides 
(forward: 5’-ATTAAAGCTTCCGGCAACATGG
TGCGGTCGGGGAATAAGGCAGCTGTTGTGC
TGTGTATGGACGTGGGC-3’ )  and  r eve r se : 
5’-ATTATCTAGACTTATC ATGTCCAATAAATC-3’). 
The engineered Ku86 gene was then sub-cloned into the 
transient mammalian expression vector pcDNA3.1/myc-
His B (Invitrogen) via digestion of the vector and cloned 
gene at the 2 restriction sites with HindIII/XbaI before 
ligating with DNA ligation kit (Stratagene, San Diego, 
USA) at 4oC overnight. The resultant ligated product was 
analysed with 1% agarose before transforming into E.coli 
with 100ug/mL ampicillin selection for amplifi cation. 
Following overnight incubation, the recombinant plasmid 
was extracted from transformed E.Coli via QIAprep Spin 
Miniprep kit (QIAGEN) and sequenced.
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Expression and Purification of Ku86 Recombinant 
Protein
The purified mammalian expression vector was 
transfected into COS-7 cells for transient expression of 
Ku86 recombinant protein. Transfection was performed by 
incubating the plasmid and Lipofectamine2000 (Invitrogen) 
with COS-7 cells grown to 90% confl uence in 175cm2 large 
fl asks as per manufacturer’s protocol. CHO cell lines were 
transfected similarly. After 24 hours, the cells were harvested 
for assays and purifi cation. For gene expression assays, 
RNA of transfected COS-7/CHO cells were extracted using 
QIAGEN RNAeasy (QIAGEN) as above and RT-PCR with 
primers Ku1 and Ku2 was performed and analysed on 1% 
agarose stained with ethidium bromide under UV light. 
Transfected COS-7/CHO cell lysates, lysed with EBC1 lysis 
buffer which contains 50mM tris pH 8.0, 150mM NaCl, 0.1% 
NP-40, 0.5ug/mL phenylmethylsulfonyl fl uoride (PMSF), 
50mM NaF, 1mM NaVO4 and one Complete® protease 
inhibitor tablet (Roche Diagnostics GmbH, Mannheim, 
Germany) in every 50mL of lysis buffer, was used for 
western immunoblotting as described. Untransfected COS-7 
was used as negative control. Ku86 recombinant protein 
was affi nity purifi ed using ProBond Nickel-Chelating Resin 
column (Invitrogen) as per manufacturer’s protocol and 
purifi ed Ku86 was confi rmed by western immunoblotting 
as described. SYPRO Ruby Gel staining was performed 
according to manufacturer’s protocol.
Western Immunoblotting
Proteins were quantified using Bradford’s method 
(BioRad, Hercules, CA) and resolved (10ug/sample) 
in a 12% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gel. Subsequently, proteins 
were transferred to a polyvinylidine difl uoride (PVDF) 
membrane (Schleicher & Schuell, Keene, NH) and blocked 
for 2 hours with 5% skimmed milk in tris-buffered saline – 
20mM tris pH 7.6,  150mM NaCl and 1% Tween-20 (Sigma-
Aldirch, St Louis, MO) with an additional 0.2% Tween-20 
(TBST). Membranes were probed using mouse monoclonal 
antibody (mAb) S10B1 for primary hybridisation and goat 
anti-mouse-HRP as secondary mAB 1:1000 dilution for 2 
hours, then washed thrice with TBST before carrying out 
chemiluminescene development with ChemiGlow reagents 
and detection with fi lmless imaging on the FluoChem 
Imager (both from Alpha Innotech, San Leandro, CA). For 
re-probing of membranes, the experiments were repeated as 
above but with the use of mouse anti-myc-HRP mAb.
Biopanning of Phage-scFvs against Ku86
The Tomlinson Library (MRC, Cambridge, UK) 
was used for phage-scFv biopanning. Four hundred 
micrograms of Ku86 in PBS was coated on Maxisorp 
immunotubes (Nalgene, Nunc, Roskilde, Denmark) for 
4oC overnight and blocked with 2% skimmed milk in 
PBS (MPBS) before addition of total 1012 phage/mL 
phage-scFv library in 2% MPBS and hybridising for 2 
hours at room temperature. Immunotubes were washed 
with PBS before and after blocking. Immunotubes were 
washed with PBS containing 0.1% Tween-20 ten times 
(20 times for rounds 2 and 3) before eluting phage-scFv. 
Panning was repeated twice with increased selection 
stringency; for rounds 2 and 3, 40 micrograms of Ku86 
in PBS was used for coating. Thereafter, phage-scFv was 
eluted with either 0.1N glycine, 1% BSA, pH 2.2 (phages 
rescued with M13K07 helper phage) or 1mg/mL trypsin-
PBS (phages rescued with KM13 helper phage) for latter 
rounds and quantitated by colony forming units (CFU). 
All eluted phage were amplifi ed by TG1 cells with 100ug/
mL ampicillin and 50ug/mL kanamycin selection before 
superinfection with either M13K07 or KM13 and purifi ed 
by Polyethylene glycol/NaCl precipitation. For polyclonal 
phage ELISA, 1010 of amplifi ed phage after panning were 
added onto immunoplates as described. For monoclonal 
phage ELISA, TG1 cells were infected with eluted phage 
for 30 minutes at 37oC and spread onto TYE/amp plates. 
After overnight incubation, TG1 colonies were randomly 
selected and inoculated into 100uL of 2xTY containing 
100ug/mL ampicillin overnight before individual clones 
superinfection with M13K07 or KM13. Phage ELISA was 
performed as described by using 100 microlitres of culture 
supernatant containing phage particles. Monoclonal phage 
verifi cation was performed similarly by using the 7 best 
binders and 7 randomly selected binders for ELISA.
Enzyme-Linked ImmunoSorbent Assay (ELISA) Analysis 
To determine antigen-binding reactivity and sensitivity of 
phage particles, serial dilutions (100ug/mL, 50ug/mL, 25ug/
mL, 12.5ug/mL and 6.25ug/mL) of purifi ed Ku86 in PBS 
were used to coat 96-well microtiter Maxisorp immunoplate 
(Nunc) at 4oC overnight. For negative and positive controls, 
100ug/mL of BSA for the former and 100ug/mL of anti-myc 
antibody for the latter was used. For monoclonal screening, 
12.5ug/mL of purifi ed Ku86 was used. After blocking the 
plate with 2% (w/v) MPBS, 1010 phage-scFv packaged 
with either M13K07 or KM13 in 2% MPBS was applied to 
each well for 1 hour at room temperature. After washing 3 
times with PBS containing 0.1% Tween-20 (PBS-Tween) 
and 3 times with PBS, the bound phage was detected with 
anti-M13 antiserum conjugated with horseradish peroxidase 
(Amersham Biosciences, GE Healthcare, Chalfont St. Giles, 
UK). The signal was visualised with TMD substrate OptEIA 
reagent (BD, San Diego, USA) and quantitated with ELISA 
microplate reader (BioRad Model 3550, Hercules, CA) at 
OD 450nm after stopping the reaction with 1M H2SO4.  
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Fig. 1b. SYPRO Ruby Gel Stain and Western blot result of Ku86 protein 
expression. Total protein gel stain using SYPRO Ruby Stain (BioRad) and 
Western immunoblotting using anti-Ku86 antibodies (S10B1) revealed that 
Ku86 was present in large amounts in transfected Monkey cell line (COS-7) 
but not the Chinese hamster ovary (CHO) cell line. Untransfected COS cells 
do not express detectable levels of human Ku86. (Lane 1: Purifi ed Ku protein; 
Lane 2: Transfected CHO cell line; Lane 3: Untransfected CHO cell line; Lane 
4: Transfected COS-7 cell line; Lane 5: Untransfected COS-7 cell line.
Fig. 1a. Western blot result for the purifi cation of Ku86 protein. The Ku86 
recombinant proteins were purifi ed using ProBond Nickel-Chelating Resin 
column. ProBond Nickel-Chelating Resin exhibits high affi nity and selectivity 
for 6xHis-tagged recombinant fusion proteins of Ku86. (Lane 1: Whole 
cell extract; Lane 2: Flow-through after binding; Lane 3: Flow-through 
after washing; Lane 4: Concentrated pure Ku protein (Eluted with 250 mM 
imidazole).
Monoclonal Phage-scFv characterisation Binding Assay
Characterisation of the binding epitopes of 2 of the best 
binding scFv clones were performed by phage serial dilution 
and competitive ELISA. Maxisorp Immunoplates were 
coated with 50ug/mL of purifi ed Ku86 in PBS overnight at 
4oC and 100ug/mL of BSA was used for negative control. 
For phage dilution, phage-scFv clones were serially 
diluted 2 fold for ELISA. For competitive ELISA, 1 mL 
of antibody mixture, which consisted of phage particles 
and known murine monoclonal antibodies (either S10B1, 
111, S5C11 or N9C1), in 2xTY was prepared while the 
plate was blocked with 2% MPBS for 2 hours at room 
temperature; murine monoclonal antibodies were added 
in increasing amounts (2.0ug/mL, 4.0ug/mL, 8.0ug/mL, 
16.0ug/mL) for each mixture. 100uL of the above antibody 
mixtures was hybridised in each well for 2 hours at room 
temperature before commencing washing and secondary 
ELISA hybridisation which was performed as above.
Results
Generation of Ku86 Antigen for Phage Display
In order to produce ScFv antibodies against the MM 
surface antigen Ku86, the protein was cloned from MM 
cell lines. Briefl y, full length gene encoding Ku86 was 
reverse engineered from MM cell lines and sub-cloned 
into mammalian expression vector pcDNA3.1/myc-His 
B. Restriction digest of the vector showed that the Ku86 
gene was of the correct size (data not shown). In addition, 
the cloned gene was fully sequenced to ensure that the 
gene was in the correct orientation and contiguous reading 
frame without any mutation. The purifi ed pcDNA3.1 vector 
was used to transfect COS-7 for expression of Ku86 and 
Ku86 antigen from COS-7 cells was purifi ed through a 
Nickel-Chelating Resin column, which exhibits a high 
affi nity and selectivity for the six His-tagged recombinant 
fusion protein of Ku86. Western immunoblotting was 
performed after purifi cation to confi rm that recombinant 
Ku86 was obtained (Fig. 1a). To examine and ascertain 
whether transfected COS-7 cells expressed recombinant 
Ku86 correctly, total protein from both transfected and 
untransfected COS-7 were either stained with SYPRO 
Ruby Protein Gel Stain or probed with anti-Ku86 antibodies 
(S10B1) in Western immunoblotting (Fig. 1b). Purifi ed 
Ku86 was used as positive control, untransfected COS-7 
was used as negative control and transfected/untransfected 
CHO cells were used as a reference. The stains and probing 
revealed that recombinant Ku86 was present in large 
amounts in transfected COS-7 while untransfected COS-
7 cells do not express detectable levels of recombinant 
Ku86. Transfected and untransfected CHO cell lines did 
not express recombinant Ku86 at all.
Biopanning and Screening for Polyclonal Antibodies against 
Ku86 by Phage ELISA
Phage display biopanning allows for the simultaneous 
screening and enrichment of the highest affi nity binders. 
The Tomlinson Library I was used to perform phage display 
biopanning against the full length Ku86 protein to obtain 
anti-Ku86 polyclonal antibodies. For the selection of good 
affi nity polyclonal antibodies, panning stringency was 
increased from round 1 to 2 by decreasing the concentration 
of antigen 10-fold and increasing the number of washes to 
remove unspecifi c binders 2-fold. The phage library was 
rescued either with trypsin-sensitive helper phage KM13 
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(eluted with tryptic treatment) or commercially available 
helper phage M13K07 (eluted with acidic glycine buffer). 
As KM13 contains a modifi ed gene 3 protein (pIII) which 
is sensitive to tryptic digestion, rescued phages containing 
only KM13 pIII and lacking wild-type pIII-scFv fusion 
are rendered non-infective after tryptic treatment while 
rescued phages with fusions are not cleaved and remain 
infective for E.Coli amplifi cation. In addition, to ensure that 
the ELISA signal refl ects the phage-scFv binding activity 
of each round accurately, different concentrations of the 
antigen, Ku86, were used for ELISA plate coating. Figures 
2a and 2b show the overall results of the biopanning and 
screening via ELISA. In general, the affi nity of phage-
scFv for Ku86 in both phage ELISAs were not substantial 
for the fi rst 2 rounds of panning as these initial rounds 
of screening were used to weed out unspecifi c and low 
affi nity binders; the decrease in binding seen in round 2 
was probably due to the increased panning stringency. As 
initial rounds of biopanning are used to fi rst select for strong 
binders before amplifying them in the third round, phage 
display biopanning was successful because polyclonal 
scFvs demonstrated an exceptional level of binding with 
more than one third increase in absorbance as compared 
to rounds 1 and 2. Interestingly, phage particles eluted 
non-specifi cally by acidic glycine buffer (Fig. 2a) showed 
a better binding to Ku86 as compared to phage particles 
eluted via trypsin treatment (Fig. 2b) by ~1.5 fold. It should 
be noted that comparison of phage ELISA data are made 
on a semi-quantitative basis. 
Isolation of Individual Clones against Ku86 by Monoclonal 
Phage ELISA
Based on these results, the third round of selection with 
the library rescued with helper phage M13K07 was used 
for isolation of monoclonal antibodies against Ku86. 
The concentration of 12.5ug/mL of Ku86 was used as 
this concentration provided a good representation of the 
binding affi nity of phage particles. To ensure that suffi cient 
clones were screened, phage particles were infected into 
TG1, plated out such that individual colonies were well 
separated before inoculating each colony into 96-well 
plates (see methods). As each phage particle only encodes 
for 1 antibody, picking individual bacterium allows us to 
investigate the binding level of monoclonal antibodies 
where ELISA absorbance readings are directly correlated 
to strength and specifi city of binding. Figure 3 illustrates 
the binding affi nities of 80 clones that were screened; all 
clones bound to Ku86 in various degrees. The majority 
of the clones had a rather low binding as judged by their 
O.D. readings (0.03 to 0.06). There were approximately 
13 modest affi nity clones and 7 good binders (clones with 
absorbance readings below 0.06 were classifi ed as weak 
binders, 0.06 to 0.08 as modest binders and readings above 
0.08 as strong binders). As monoclonal phage particles 
bind to specifi c epitopes, it is expected that the majority 
of the clones do not bind well and that only a few clones 
would have a high specifi city and avidity for Ku86 which 
was refl ected in Figure 3. Furthermore, O.D. readings for 
monoclonal strong binders are expected to be lower as 
compared to polyclonal ELISA studies (O.D. ~ 0.22 at 
12.5ug/mL) because the O.D. readings from polyclonal 
Fig. 2a. ELISA readings for 3 rounds of polyclonal antibodies biopanning 
rescued with M13K07 helper phage and eluted with non-specifi c acidic glycine 
buffer. Biopanning results were indistinct at low concentrations of antigen 
(6.25ug/mL). At antigen concentrations of 12.5ug/ml and above, Round 3, 
the expansion and amplifi cation round of biopanning shows more than 1/3 
increase in ELISA absorbance and binding as compared to Round 1 (  ) and 
2 (  ). BSA (100ug/mL) was used as negative control. 
Fig. 2b. ELISA readings for 3 rounds of polyclonal antibodies biopanning 
rescued with KM13 helper phage and eluted with specifi c trypsin treatment. 
Biopanning results were inaccurate at low concentrations of antigen (6.25ug/
mL). At antigen concentrations of 12.5ug/ml and above, Round 3 (  ), the 
expansion and amplifi cation round of biopanning shows more than 1/3 
increase in ELISA absorbance and binding as compared to Round 1 (  ) and 
2 (  ).  BSA (100ug/mL) was used as negative control. 
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Fig. 4. ELISA results of monoclonal antibody phage verifi cation. The ELISA 
plate was coated with 12.5ug/ml of antigen. All stronger binders (  ) had a 
better absorbance and affi nity as compared to the random wells (  ) selected 
for comparison. However, 3 of the strong binders ‘J2, J8 and H6’ had lower 
than expected binding as compared to Figure 3. Wells H3, A6, G3 and G6 
showed approximately 2-fold higher absorbance and increased binding 
compared to the random wells. 
Fig. 5a. ELISA absorbance readings of phage ScFv-Ku86 dilution experiments. 
Both ScFvs, A6 (  ) and G6 (  ) showed antigen-dependent binding. 
screening measures the overall combinatorial binding 
from all the monoclonal antibodies on different epitopes 
which allows for increased antibody-antigen interactions 
and higher readings.
Use of Phage ELISA to Verify Monoclonal Phage 
Particles
To ensure that the monoclonal phage-scFvs that were 
identifi ed by ELISA screening were not false positives, 
strong binders were further examined with randomly chosen 
clones by phage ELISA at 12.5ug/mL Ku86 concentration. 
As depicted in Figure 4, all strong binders had better 
binding as compared to the 7 randomly selected binders in 
general. Interestingly, 3 of the strong binders which were 
chosen from monoclonal isolation (wells J2, J8 and H6) 
had absorbance readings of OD650nm ~ 0.08-0.09 which were 
approximately similar to the randomly selected binders and 
were substantially lower as compared to previous fi ndings. 
Thus, for further confi rmation, PCR was performed on the 
7 strong binders and analysed on agarose gel. The PCR 
analysis confi rmed that wells H3, A6, G3 and G6 had full-
length variable heavy (VH) and variable light chain (VL) 
while there were no bands seen for wells J2 and H6 and well 
J8 had only half the required length. In addition, the strong 
binders were sequenced and the Basic Local Alignment 
Search Tool (BLAST) was performed, confi rming the 
above 4 wells had both VH and VL while the sequence of 
J8 showed that no VH was present and wells J2 and H6 
revealed sequences from the cloning vector only.
Phage ELISA and Inhibition Experiments for Characterisa-
tion of Binding Epitopes
Anti-Ku86 monoclonal antibody candidates, clones 
A6 and G6, which were identifi ed by ELISA screenings, 
were further examined to determine their binding sites on 
Ku86 epitopes. They were thus tested as phage-scFvs in 
conjunction with other known antibodies for their potential 
to bind to Ku86 in competitive ELISAs. The fi rst set of 
experiments, illustrated in Figure 5a, shows that both 
phage-scFv clones A6 and G6 bind to Ku86 in a specifi c 
Fig. 3. ELISA readings for monoclonal antibody screening and selection. 
ELISA plate wells were coated with 12.5ug/ml.The abscissa (A-J) denotes 
the column which corresponds to the column of the 96-well plate and the 
colored bars denotes the row of the 96-well plate. The ‘Strong binders’ (above 
0.08absorbance) were A6, G6, G3, H6, H3, J8 and J2 and used for ELISA 
phage verifi cation
July 2009, Vol. 38 No. 7
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and dose-dependent manner. Subsequently, to determine 
the binding sites on Ku86, phage particles were incubated 
in competitive ELISAs with several murine monoclonal 
anti-Ku86 antibodies: S10B1, 111, S5C11 and N9C1, which 
are specifi c for human and monkey Ku proteins. For S10B1 
and 111 competitive ELISA assays, no signifi cant change 
in binding levels were seen with increasing amounts of 
antibodies (data not shown), indicating that clones A6 and 
G6 probably do not have recognition for epitopes targeted 
by S10B1 (C-terminal) or 111 (N-terminal). Conversely, 
competitive experiments of clone A6 with S5C11 revealed 
dramatically decreased binding of A6 when S5C11 
concentrations were increased (Fig. 5b) while competitive 
experiments of clone G6 with N9C1 (Fig. 5c) showed a minor 
decrease. G6/S5C11 and A6/N9C1 competitive experiments 
did not reveal any signifi cant change in binding levels (data 
not shown). These results suggest that clone A6 and G6 
may be binding near the aa506-541 epitope (S5C11) and 
aa1-374 (N9C1) epitope, respectively.
Discussion
The development of therapeutic antibodies has been 
explored by many institutions and organisations because 
of their potency in fi nding, and binding to, typically any 
kind of molecule with high affi nity and specifi city.24 
Examples of antibodies which have progressed from the 
laboratory to the clinic include, but are not limited to, the 
following: Rituximab and Zevalin (Anti-CD20) for Non-
Hodgkin lymphoma, Alemtuzumab (Anti-CD52) for B-cell 
lymphocytic leukemia and Mylotarg (Anti-CD33) for 
acute myeloid leukaemia. As studies to isolate antibodies 
against Ku using classical hybridoma technology were not 
very successful in our laboratory (unpublished data) and 
screening of recombinatorial phage display libraries for the 
isolation prototype antibody against cancer have become 
one of the main approach to therapeutic and diagnostic 
drug discovery and validation, phage display technology 
was used here to isolate several clones for further studies 
on MM in the hope of developing the clones for therapeutic 
use in the future. Antibody isolation was successful and 
enhancement of mAbs can be subsequently performed via 
molecular engineering or directed evolution if necessary. 
Synthesising of whole and humanised anti-Ku86 antibodies 
and subsequent scaling up antibody production in a GMP 
facility as well as performing animal proof-of-concept 
studies will be performed in future studies.
The Ku heterodimer plays a central role in several 
nuclear processes ranging from DNA repair, telomere 
maintenance to cell proliferation and apoptosis making it a 
highly important regulatory protein.15,19,20,25 Indeed, recent 
reports have implicated that the Ku protein (or its variant) 
partakes in the development of several cancers, notably 
MM.19 In MM, Ku has been shown to translocate to the 
cell membrane upon CD40-activation and are involved 
in homotypic and heterotypic cell-cell adhesion as well 
as adhesion to fi bronectin which protects the MM cell 
from apoptosis triggered by irradiation or doxorubicin.21,22 
Further, reports on Ku86 variant protein (Ku86v) expression 
in MM have shown that increased expression of Ku86v is 
correlated with an increased sensitivity to DNA damage.26 
Finally, antibodies against surface Ku86 (5E2) were shown 
to induce apoptosis in MM cells.22 Taken together, the 
Ku protein could be an important candidate for anti-MM 
drug development. Here, the generation of these human 
scFv clones against Ku86 provides a potentially important 
diagnostic tool, which can be used for further studies on 
Fig. 5b. Competitive ELISA assay for phage-ScFv A6 with S5C11 antibody. 
Increasing amounts of S5C11 resulted in a 2/3 drop in absorbance reading 
from ~0.2 to ~0.05 where further increases had no further effect.
Fig. 5c. Competitive ELISA assay for phage-ScFv G6 with N9C1 antibody. 
Increasing amounts of N9C1 by half resulted in a ~1/5 drop in absorbance 
readings at each dilution point. 
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the role of Ku, its variant and understanding their link to 
the development of MM. Importantly, these clones form 
the basis upon which an anti-MM therapeutic agent could 
be engineered given that although there are several good 
affi nity antibodies directed against the Ku protein available 
commercially at the moment, none of these are human in 
origin or suitable for use as therapy.
The functional display of antibodies on phage particles 
using large diverse combinatorial libraries opens 
possibilities to select specifi c antibodies against proteins 
or antigens of interest which subsequently allows for the 
basis with which the antibody could be studied, improved 
or altered.27 Screening of these libraries typically allows for 
the selection of antibodies with high affi nities, ranging from 
micromolar to nanomolar affi nity constants, depending on 
the size and diversity of the library.28 Following screening 
and binding selection, it is then possible to deduce the 
primary structure of the binding site of the antibody by 
sequencing the clone’s DNA due to the linking of phenotype 
to the genotype encoding that molecule within the same 
virion. Here, in this study, several scFv clones have been 
isolated against the Ku86 protein using phage display as 
a preliminary effort to target the effect of Ku86 in MM. 
After selection, nucleotide sequence analysis have been 
performed on the clones to confi rm that selected clones 
contained both human VH and VL sequences before 
subjecting them to comparative studies with commercially 
available Ku86 antibodies.
Since its advent approximately 30 years ago, the classical 
hybridoma method is still being used to generate mAbs.29 
Although this conventional technology has a successful 
history, it has several intrinsic limitations: namely, its 
relatively longer time span to isolate antigen-specifi c 
antibodies (a time measured in months as compared to 
weeks using phage display), its immunogeneticity where 
murine antibodies may result in patients developing  HAMA 
reactions, presence of an affi nity ceiling, the diffi culty in 
controlling in vivo selection conditions and the subsequent 
antibody specifi city and affi nity. Antibody fragments or 
single chain Fvs’, displayed on phage surfaces, bypass 
these problems and allow for an in vitro optimisation 
of antibodies against the specifi c antigen. Phage display 
has proven to be a faster, more fl exible and more reliable 
alternative to generation and selection of antibodies.30 
Carried out in the test tube, with human VH and VL chain 
genes, the selection process is remarkably similar to the 
natural affi nity maturation process of affi nity selection 
and somatic hypermutation where it allows for tightly 
controlled conditions, comparatively shorter time selection 
without a need for superhumanising and isolation of human 
antibodies with higher affi nities that are not easily achieved 
in hybridoma.
Despite the fact that phage display is relatively simple 
to use and its phage particles are robust and stable, this 
system has a few constraints such as library antibody 
diversity limitation and erroneous amplifi cation of a low 
affi nity clone30-33 and diffi culties in the reproducibility of 
the ELISA O.D. measurements. Antibody diversity and the 
subsequent possibility of isolating high affi nity antibodies 
are directly linked to the size of the library. As the synthesis 
and assembly of phage particles occurs in bacteria, 
the DNA encoding the antibody needs to be imported 
artifi cially. Thus, the recombinatorial library is limited 
by bacterial transforming effi ciency and this is presented 
as a disadvantage where the largest reported libraries are 
made of not more than 1x1010 to 1x1011 members currently. 
Amplifi cation of antibodies during screening is directly 
linked to the phage with the highest growth advantage 
(with or without antibody fusion) and combined with the 
‘sticky’ properties of phages, therein lies the possibility 
that only low affi nity clones dominate a population after 
screening (erroneous amplifi cation). A low affi nity clone 
may arise due to several factors such as the failure of the 
antibody fragment to be expressed or folded properly, the 
susceptibility of the clone to proteolysis or the fact that the 
fragment is toxic to the host and forming aggregates which 
slows down or stops bacterial growth.30
In summary, the experiments described here have isolated 
good affi nity scFvs against Ku86. These clones form the 
basis upon which further experiments can be performed to 
develop the antibodies into therapeutic anti-cancer agents. 
Further, here we show that an established method (phage 
display) other than the classical hybridoma technology 
could be used for antibody selection as a proof of principle 
that mAbs may be generated in a shorter period of time 
and, because a recombinatorial human antibody library 
was used, could offer a signifi cant clinical advantage over 
murine antibodies by avoiding HAMA reactions.
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